Merck Weighs Use of COVID Antiviral Molnupiravir in Response to Ebola Outbreak
Merck is engaging with global health authorities about whether its COVID-19 antiviral pill, molnupiravir (Lagevrio), could be deployed against a widening Ebola outbreak in the Democratic Republic of Congo caused by the Bundibugyo strain. Company officials said the drug is a non-specific RNA virus therapy, has shown efficacy against Ebola in animal …